08:00 , Jan 25, 2016 |  BC Week In Review  |  Financial News

20/20 GeneSystems completes venture financing

20/20 GeneSystems Inc. , Rockville, Md.   Business: Diagnostic   Date completed: 2016-01-14   Type: Venture financing   Raised: $4.5 million   Investors: Ping An Ventures; and other undisclosed investors  ...
02:34 , Jan 16, 2016 |  BC Extra  |  Financial News

20/20 GeneSystems raises $4.5M in series A

Diagnostic play 20/20 GeneSystems Inc. (Rockville, Md.) raised $4.5 million in a series A round. Investors included Ping An Ventures, which is the venture capital division of China's largest insurance company, and affiliates of angel...
07:00 , Sep 1, 2014 |  BC Week In Review  |  Financial News

20/20 GeneSystems completes venture financing

20/20 GeneSystems Inc. , Rockville, Md.   Business: Diagnostic   Date completed: 2014-08-18   Type: Venture financing   Raised: Not disclosed   Investor: Bao Hao Investment Management   Note: The amount raised was not disclosed....
23:27 , Aug 22, 2014 |  BC Extra  |  Financial News

Bao Hao buying stake in 20/20 GeneSystems

A U.S. affiliate of China's Bao Hao Investment Management Co. Ltd. will pay an undisclosed amount to acquire an equity stake in diagnostics company 20/20 GeneSystems Inc. (Rockville, Md.). 20/20 GeneSystems markets PAULA's blood test...
07:00 , Sep 24, 2012 |  BC Week In Review  |  Clinical News

PredicTOR diagnostic data

An exploratory study analyzing tumor samples surgically removed prior to treatment with Herceptin trastuzumab from 45 patients with HER2-positive breast cancer showed that 20/20 GeneSystems' PredicTOR test correctly identified 28 of 32 tumors that ultimately...
07:00 , Mar 12, 2012 |  BC Week In Review  |  Company News

20/20 GeneSystems sales and marketing update

20/20's Genesys BioLabs division launched PAULA's blood test for the early detection of lung cancer. The test scores patients' risk of lung cancer based on analysis of six blood-based biomarkers to assist physicians with triaging...
08:00 , Jan 21, 2008 |  BC Week In Review  |  Company News

20/20 GeneSystems, J&J deal

Johnson & Johnson 's Ortho-Clinical Diagnostics subsidiary received a co-exclusive license to 20/20's blood test that identifies antibody responses to early stage non-small cell lung cancer (NSCLC). Ortho-Clinical will pay undisclosed upfront fees and development...
07:00 , Aug 21, 2006 |  BC Week In Review  |  Clinical News

Blood test for lung cancer diagnostic data

Researchers published in the Journal of Thoracic Oncology that a blood screen test was able to detect non-small cell lung cancer (NSCLC) with 82.6% accuracy. The blood screen was able to predict 32 of 40...
07:00 , Oct 14, 2002 |  BC Week In Review  |  Company News

20/20 GeneSystems, Novartis deal

The companies will use 20/20's Protein Function Identification Layered Membranes (P-FILM) technology to study protein expression and activation patterns in tumor samples provided by NVS. NVS will fund the project, which aims to identify protein...
07:00 , Oct 8, 2001 |  BC Week In Review  |  Company News

20/20 GeneSystems sales and marketing update

GeneSystems launched its layered proteomics technology for simultaneously screening activation levels, quantities and locations of proteins in tissue from a single biological sample. 20/20 GeneSystems Inc., Rockville, Md.   Business: Proteomics  ...